While SARS2 challenge led to overall higher pulmonary lesion scores later (6 days post challenge (dpc)) in infection than in the FLUAV pre-exposure group, FLUAV pre-exposed GSHs displayed slightly more pronounced pathology in the NT and lungs at 3 dpc. This evidence concerns the gene SARS2 and infection.